Literature DB >> 21402832

Activity of carbapenems combined with clavulanate against murine tuberculosis.

Nicolas Veziris1, Chantal Truffot, Jean-Luc Mainardi, Vincent Jarlier.   

Abstract

Although beta-lactam antibiotics are not considered as antituberculous drugs, it has been recently shown that the combination of carbapenems and clavulanate is bactericidal in vitro. We evaluated in a murine model of tuberculosis the activity of carbapenems alone and combined with clavulanate against Mycobacterium tuberculosis. Swiss mice infected intravenously with 3 x 10⁵ M. tuberculosis H37Rv were treated for 4 weeks with clavulanate alone or imipenem, meropenem, and ertapenem alone or combined with clavulanate, whereas a positive control group was treated with isoniazid, and a negative control group was held without treatment. The combination of imipenem or meropenem plus clavulanate significantly improved survival. Among groups of mice with 100% survival, only isoniazid reduced lung CFU counts; the carbapenem-clavulanate combinations did not prevent bacterial growth. Although less active than isoniazid, the combinations of imipenem or meropenem plus clavulanate improved the survival of mice infected with M. tuberculosis and should be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402832      PMCID: PMC3101399          DOI: 10.1128/AAC.01824-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Global incidence of multidrug-resistant tuberculosis.

Authors:  Matteo Zignol; Mehran S Hosseini; Abigail Wright; Catharina Lambregts-van Weezenbeek; Paul Nunn; Catherine J Watt; Brian G Williams; Christopher Dye
Journal:  J Infect Dis       Date:  2006-07-12       Impact factor: 5.226

2.  Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.

Authors:  Sutep Jaruratanasirikul; Nuntida Raungsri; Jarurat Punyo; Somchai Sriwiriyajan
Journal:  J Antimicrob Chemother       Date:  2005-10-18       Impact factor: 5.790

3.  Extensively drug-resistant tuberculosis--United States, 1993-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-03-23       Impact factor: 17.586

4.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-03-24       Impact factor: 17.586

5.  Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Authors:  N Veziris; N Lounis; A Chauffour; C Truffot-Pernot; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Authors:  Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

7.  Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate.

Authors:  Jean-Emmanuel Hugonnet; John S Blanchard
Journal:  Biochemistry       Date:  2007-10-04       Impact factor: 3.162

8.  Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.

Authors:  Jean-Luc Mainardi; Jean-Emmanuel Hugonnet; Filippo Rusconi; Martine Fourgeaud; Lionel Dubost; Angèle Nguekam Moumi; Vanessa Delfosse; Claudine Mayer; Laurent Gutmann; Louis B Rice; Michel Arthur
Journal:  J Biol Chem       Date:  2007-07-23       Impact factor: 5.157

9.  Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infections.

Authors:  R J Boon; A S Beale; K R Comber; C V Pierce; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

10.  Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance.

Authors:  N Veziris; C Martin; F Brossier; F Bonnaud; F Denis; A Aubry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 5.103

View more
  26 in total

1.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  The role of the β5-α11 loop in the active-site dynamics of acylated penicillin-binding protein A from Mycobacterium tuberculosis.

Authors:  Alena Fedarovich; Robert A Nicholas; Christopher Davies
Journal:  J Mol Biol       Date:  2012-02-23       Impact factor: 5.469

3.  Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.

Authors:  Shashikant Srivastava; Sander P van Rijn; A Mireille A Wessels; Jan-Willem C Alffenaar; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 4.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Authors:  M A Zuur; S Ghimire; M S Bolhuis; A M A Wessels; R van Altena; W C M de Lange; J G W Kosterink; D J Touw; T S van der Werf; O W Akkerman; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

Authors:  Sander P van Rijn; Shashikant Srivastava; Mireille A Wessels; Dick van Soolingen; Jan-Willem C Alffenaar; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors:  Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth.

Authors:  Nathan Wlodarchak; Nathan Teachout; Jeffrey Beczkiewicz; Rebecca Procknow; Adam J Schaenzer; Kenneth Satyshur; Martin Pavelka; William Zuercher; David Drewry; John-Demian Sauer; Rob Striker
Journal:  Mol Pharm       Date:  2018-10-18       Impact factor: 4.939

Review 10.  β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.